Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting

Aclaris Therapeutics (NASDAQ: ACRS) announced an ePoster presenting previously unreported results from its open-label Phase 2a trial of ATI-2138 for moderate-to-severe atopic dermatitis at the 2026 AAD Annual Meeting in Denver, CO on March 20, 2026.

Rhea-AI Summary

Aclaris Therapeutics (NASDAQ: ACRS) announced an ePoster presenting previously unreported results from its open-label Phase 2a trial of ATI-2138 for moderate-to-severe atopic dermatitis at the 2026 AAD Annual Meeting in Denver, CO on March 20, 2026.

ATI-2138 is described as an investigational oral covalent inhibitor targeting ITK and JAK3. The poster lists Aclaris and Mount Sinai authors and will be available electronically during the meeting.

Argus Mar 20 session

-1.34% close to close Open Argus

Details

News Market Reaction – ACRS

In the Mar 20 session, ACRS declined 1.34%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement adds visibility to ATI‑2138 by sharing new Phase 2a atopic dermatitis data at the ...

Analysis

This announcement adds visibility to ATI‑2138 by sharing new Phase 2a atopic dermatitis data at the 2026 AAD meeting. It follows recent milestones including bosakitug Phase 2 enrollment completion and multiple early-stage studies in immuno‑inflammatory diseases. Filings show cash of $151.4M as of year‑end 2025 and additional equity raises of $39.8M and $20.0M, but also a $64.9M net loss in 2025. Investors may watch for detailed ATI‑2138 efficacy, safety, and any future trial plans.

Key Figures

Phase: Phase 2a Patients enrolled: 109 patients Cash balance: $151.4M +5 more

Phase

Phase 2a

Open-label trial of ATI-2138 in atopic dermatitis

Patients enrolled

109 patients

Bosakitug Phase 2 atopic dermatitis trial

Cash balance

$151.4M

Cash, cash equivalents and marketable securities as of Dec 31, 2025

Net loss 2025

$64.9M

Full-year 2025 net loss

Net loss 2024

$132.1M

Full-year 2024 net loss

Revenue 2025

$7.8M

Full-year 2025 total revenue

ATM proceeds

$39.8M

Aggregate gross proceeds from 12.7M shares sold Mar 2–9, 2026

ATM proceeds

$20.0M

Aggregate gross proceeds from 5.7M shares sold on Mar 10, 2026

Historical Context

5 past events · Latest: Mar 18

5 events

1. Mar 18

   Clinical enrollment update

   24h Move

   -5.7%

   Completed enrollment of 109‑patient Phase 2 bosakitug atopic dermatitis trial.

2. Mar 03

   Conference participation

   24h Move

   -0.3%

   Planned fireside chat at Leerink healthcare conference with webcast access.

3. Feb 26

   Earnings and update

   24h Move

   -5.4%

   Reported 2025 results, positive pipeline progress and cash of $151.4M with runway.

4. Feb 24

   Trial initiation

   24h Move

   +3.4%

   Initiated Phase 1b proof‑of‑concept ATI‑052 asthma trial with H2 2026 readouts.

5. Feb 04

   Conference appearances

   24h Move

   +2.0%

   Announced participation in two February healthcare conferences with management talks.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

interleukin-2-inducible t cell kinase, janus kinase 3, atopic dermatitis

3 terms

interleukin-2-inducible t cell kinase medical

"ATI-2138, a potent and selective investigational oral covalent inhibitor of interleukin-2-inducible T cell kinase (ITK)"

Interleukin-2-inducible T cell kinase (ITK) is a protein inside certain immune cells that acts like a control switch, helping those cells respond to signals and coordinate immune reactions. For investors, ITK matters because medicines that block or modify this switch can change how the immune system fights disease — making it a common drug target for autoimmune disorders, allergic conditions and some cancer therapies; progress or setbacks in developing ITK-targeting drugs can materially affect a company’s clinical and commercial prospects.

janus kinase 3 medical

"oral covalent inhibitor of interleukin-2-inducible T cell kinase (ITK) and Janus kinase 3 (JAK3)"

Janus kinase 3 (JAK3) is a protein inside immune cells that acts like a signaling switch, turning on or off responses to infections and inflammation when certain receptors are engaged. Investors care because drugs that block or modify JAK3 can change the course of autoimmune diseases, transplant rejection and some cancers, so progress, safety results or regulatory decisions around JAK3-targeting therapies can meaningfully affect a company’s drug pipeline value and market prospects.

atopic dermatitis medical

"Phase 2a trial in patients with moderate-to-severe atopic dermatitis (AD)"

A chronic inflammatory skin condition, often called eczema, that causes dry, itchy, red patches and recurring flare-ups; think of it as a persistent rash that can come and go over a person’s life. It matters to investors because its chronic nature and large patient population create steady demand for treatments, influence drug development and approval decisions, affect healthcare costs and reimbursement, and can drive revenue and valuation shifts for companies working on therapies and diagnostics.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WAYNE, Pa., March 20, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that an ePoster on the results from its open-label Phase 2a trial of ATI-2138, a potent and selective investigational oral covalent inhibitor of interleukin-2-inducible T cell kinase (ITK) and Janus kinase 3 (JAK3), will be available during the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, CO. The poster will include results not previously reported from Aclaris’ Phase 2a trial in patients with moderate-to-severe atopic dermatitis (AD).

Electronic Poster Details:

Title	Results from an Open-Label Phase 2 Trial of ATI-2138, an Investigational Oral Covalent Inhibitor of Interleukin-2-Inducible T Cell Kinase (ITK) And Janus Kinase 3 (JAK3), in Patients with Moderate-To-Severe Atopic Dermatitis
Authors	Ajay Aggarwal1, Aparna Kaul1, Loreen Stillwell1, Nancy McGraw1, Robert Mahe1, Rakesh Basavalingappa1, Emma Huff1, David R. Anderson1, Emma Guttman2, Joseph Monahan1, Neal Walker1
	Affiliations: 1Aclaris Therapeutics Inc.; 2Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn.
        
Aclaris Therapeutics Contact:

Will Roberts
Senior Vice President
Corporate Communications and Investor Relations
(484) 329-2125
wroberts@aclaristx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Aclaris (ACRS) announce about ATI-2138 at the 2026 AAD Annual Meeting?

Aclaris announced an ePoster with previously unreported Phase 2a results for ATI-2138 in moderate-to-severe atopic dermatitis. According to Aclaris, the poster reports data from an open-label Phase 2a trial and will be available electronically during the 2026 AAD meeting in Denver.

What is ATI-2138 and what mechanisms does Aclaris (ACRS) report for it?

ATI-2138 is an investigational oral covalent inhibitor of ITK and JAK3. According to Aclaris, the molecule is designed to selectively inhibit interleukin-2-inducible T cell kinase and Janus kinase 3, mechanisms relevant to immune signaling in atopic dermatitis.

When and where will the Aclaris (ACRS) Phase 2a ePoster for ATI-2138 be available?

The ePoster will be available during the 2026 American Academy of Dermatology Annual Meeting in Denver, CO. According to Aclaris, electronic poster details and author affiliations will be accessible during the conference held in March 2026.

What patient population did Aclaris (ACRS) study in the ATI-2138 Phase 2a trial?

The trial enrolled patients with moderate-to-severe atopic dermatitis. According to Aclaris, the Phase 2a study was open-label and specifically evaluated ATI-2138 in individuals with moderate-to-severe AD to generate the data presented in the ePoster.

Who authored the Aclaris (ACRS) ePoster on the ATI-2138 Phase 2a trial presented at AAD 2026?

The ePoster lists Aclaris clinical authors and a Mount Sinai dermatology coauthor. According to Aclaris, listed authors include Aclaris staff and one Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, collaborator.

Does the Aclaris (ACRS) announcement include detailed trial outcomes or efficacy numbers for ATI-2138?

The announcement states the ePoster includes results not previously reported but does not list specific efficacy figures in the notice. According to Aclaris, detailed numeric outcomes and data will be available within the electronic poster at the AAD meeting.